The Urinary Microbiome in Patients Receiving Intradetrusor Botox Injections

The Urinary Microbiome Before and After Treatment With Intradetrusor Onabotulinum Toxin A Injection for Overactive Bladder

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04479709

Enrollment

Registered

2020-07-21

Start date

2021-01-01

Completion date

2022-06-30

Last updated

2024-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder

Keywords

Overactive bladder, Urinary microbiome

Brief summary

An altered urinary microbiome (UM) may explain the symptoms in overactive bladder (OAB) patients who were previously considered to have idiopathic OAB. To date, most research on the relationship between OAB and the UM has focused on differentiating between the UM of a normal bladder and that of an OAB bladder. There is currently a paucity of data on the way that OAB therapy impacts the UM. One of the few studies to evaluate the UM pre- and post-OAB treatment focused on how management with solifenacin affected the UM, but no studies have evaluated how intravesical onabotulinumtoxin A injections (IOI) affects the UM. Understanding IOI's impact on the UM is particularly interesting because despite both anticholinergics and IOI exerting antimuscarinic affects on the bladder, IOI is often successful when anticholinergics are not. This raises the question of what other mechanisms of action IOI may have in the bladders of OAB patients - one hypothesis is that it might stabilize the UM in those select patients who suffer from OAB due to an altered UM. The primary objective of this study is therefore to determine the UM profiles of OAB patients before and after treatment with IOI.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 89 Years

Inclusion criteria

\- Women undergoing intradetrusor botox injection with botox 100 U

Exclusion criteria

* Current UTI * History of recurrent UTI * History of antibiotic exposure for any reason (including if response is unknown) * Antibiotic exposure for any reason other than post-procedure prophylaxis during the four-week follow-up period.

Design outcomes

Primary

Measure	Time frame	Description
Urinary Microbiome	08/2020 - 08/2021	To evaluate whether administration of intradetrusor botox injections for the treatment of overactive bladder results in changes to the urinary microbiome.

Secondary

Measure	Time frame	Description
Urinary Microbiome by response	08/2020 - 08/2021	To evaluate whether there are differences between responders and non-responders to intradetrusor botox injections in the pre- and post-treatment urinary microbiomes.
Urinary tract infection	08/2020 - 08/2021	Determine if there is a relationship between pre- or post-intradetrusor botox injection and the rate of urinary tract infection.
Adverse events	08/2020 - 08/2021	Adverse events from intradetrusor botox injection

Countries

United States

Outcome results